AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$RPRX

Coyne Terrance P. sold $646K of RPRX (indirect holdings)

Coyne Terrance P. (EVP & CFO) sold 11,002 indirectly-held shares of Royalty Pharma plc (RPRX) at an average of $58.68 ($58.59–$59.14, $0.65M total) across 2 trades on 2026-08-13 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Coyne Terrance P.
Published Aug 17, 2026, 9:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 17, 2026, 9:10 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$RPRX
Neutral
high confidence
Mentioned
$RPRX
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RPRXNeutralLow
01

Why it matters

The disclosure updates the insider trading record for RPRX, but it does not provide new operational or financial information about the company.

02

Market read

Traders may briefly reassess sentiment around RPRX due to the CFO’s sale, but the 10b5-1 structure limits interpretive value.

03

What to watch

The filing shows the executive ended with 0 shares, but it provides no context on total holdings before the plan, tax needs, or diversification motives.

Relevance 4/10Novelty 5/10Timing: filed Aug. 17, trades executed Aug. 13 (after-hours filing impact)

Background

SEC Form 4 reports an insider transaction by Royalty Pharma plc EVP and CFO Terrance P. Coyne.

Company-level read

Ticker impact

$RPRXNeutralHigh confidence
Context

Royalty Pharma CFO Coyne sold $645,551 of RPRX shares via a 10b5-1 plan, leaving 0 shares after the Aug. 13 trades.

Expected impact

Likely limited, with any impact more sentiment-driven than fundamental.

Evidence & confidence

The filing is a Form 4 insider transaction with a pre-arranged 10b5-1 plan; it does not include new company performance, guidance, or regulatory/contract developments.

Market effects

Sector

Minimal; insider sales in a single large pharma royalty name typically do not reset sector expectations.

Regional

Minimal; US-listed ADR-style sentiment effect only.

Global

Minimal; no cross-border deal, trial, or regulatory action described.

Counterpoint

What could challenge this read

Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect routine liquidity rather than bearish expectations.

Key entities

  • issuer
    Royalty Pharma plc

    Company whose shares were sold by an EVP and CFO under a 10b5-1 plan.

  • insider
    Terrance P. Coyne

    EVP and CFO who executed open-market sales totaling $645,551.21.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

RPRX insider trading history →

Related articles

$RPRXHighAI 8/10

Royalty Pharma PLC (RPRX) (Q3 2026) Earnings Call Highlights: Raised Guidance, Strong

Royalty Pharma (RPRX) reported 9% Q3 2026 royalty receipts growth, raising full-year guidance to $3.5-3.55B. ROIC was 14.3%, ROIE 20.2%. Deployed $1.6B in capital, with a 90% success rate in development-stage portfolio. Challenges include a $150M impairment charge from Novartis' pelacarsen failure and declining royalties from key products. Management discussed growth opportunities, including Amgen's olpasiran and China's biotech sector.

finance.yahoo.com
$RPRXMedAI 8/10

Royalty Pharma plc Q3 2026 Earnings Call Summary

Royalty Pharma reported 9% growth in Q3 2026 Portfolio Receipts and raised full-year guidance to $3.5B-$3.55B. The company invested $1.6B in new royalties and returned $590M to shareholders. Management highlighted growth opportunities in pharma R&D co-funding and expansion in China, while maintaining a AAA ESG rating.

finance.yahoo.com
$RPRXMedAI 8/10

Royalty Pharma Q3 Earnings Call Highlights

Royalty Pharma acquired Zealand Pharma's royalty interest in Takeda's MIMRYLO for $100M, receiving 1% royalties on sales up to $1.5B and 0.75% above that. It also paid AstraZeneca $100M for a 3% royalty on ZORYVE sales. The company reported FDA approvals for RASONQUE and WELTRUZA, and positive phase III results for IMDELLTRA and deucrictibant XR. Royalty Pharma highlighted $1B in R&D co-funding deals, including a $500M agreement with Teva, and expansion in China.

finance.yahoo.com
$RPRXMed

Royalty Pharma (RPRX) Q3 2026 Earnings Call Transcript

Royalty Pharma (RPRX) reported Q3 2026 earnings, highlighting $1.6B in capital deployment, including acquisitions of royalties on Arcutis' Zoryve and Takeda's Mimrylo. The company raised 2026 guidance, citing strong portfolio performance and positive clinical updates. It returned $590M to shareholders through dividends and buybacks. Management emphasized robust deal pipeline and consistent double-digit growth since IPO.

finance.yahoo.com
$RPRXMedAI 8/10

Royalty Pharma Q3 2026 slides: guidance raised, new royalties acquired

Royalty Pharma (RPRX) reported Q3 2026 earnings with $890M in portfolio receipts, up 9% YoY. Adjusted EPS of $1.21 beat estimates. The company raised full-year guidance and announced $1.6B in capital deployment, including two new royalty acquisitions. Shares fell 1.81% despite a 79% rally over the past year. The company highlighted strong portfolio growth and pipeline progress, with multiple FDA approvals and positive Phase 3 results.

investing.com